Page 99 - Contract Development News Today

Press release content from Globe Newswire. The AP news staff was not involved in its creation. MATEON PARTNERED WITH CHOPRA FOUNDATION ON ARTIVEDA™ Mateon Therapeutics, Inc.February 16, 2021 GMT AGOURA HILLS, California, Feb. 16, 2021 (GLOBE NEWSWIRE) --  Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health, announced a global partnership with Chopra Foundation, a non-profit, to collaborat...

CDMOs: value-based pricing is key to success SHARES Many pharmaceutical and biotech companies outsource their product development and manufacturing. In this article, experts from Simon-Kucher & Partners explain why smart offer design and costing is key to commercial success for CDMOs. Contract Development and Manufacturing Organisations (CDMOs), to which pharmaceutical companies increasingly outsource product development and manufacturing, currently operate in a highly fragmented market that is...

Regulatory News: Eurofins (Paris:ERF) launches a new CE marked serological assay for the identification and quantification of antibodies to SARS-CoV-2. This ELISA kit can support vaccination campaigns

Share this article Share this article to reach USD 10.4 billion by 2028, according to a new report by Grand View Research, Inc., expanding at a CAGR of 6.9% from 2021 to 2028. The increasing prevalence of chronic diseases in animals and growing concerns among pet owners are the key contributors to the market growth. Key suggestions from the report: The contract outsourcing service type accounted for the largest revenue share of over 58% in 2020 owing to associated benefits with its usage The g...

Wuxi STA to Acquire Bristol Myers Squibb’s Manufacturing Unit in Switzerland Switzerland: Pharma Deal Wuxi STA to Acquire Bristol Myers Squibb’s Manufacturing Unit in Switzerland 04.02.2021Editor: Ahlam Rais Located in Couvet, Switzerland, Bristol Myers Squibb’s manufacturing facility will be Wuxi STA’s first plant in Europe. On completion of the deal, Wuxi STA is expected to acquire the Couvet site’s operations and assets. Related Companies ...

Recipharm and Medspray Launch Resyca Joint Venture to Exploit Novel Softmist Technology for Pharmaceutical Applications Monday, 01 February 2021 18:00 Hits: 6982   ENSCHEDE, the Netherlands, February 01, 2021 / B3C newswire / --Recipharm AB (publ) (“Recipharm”), a leading contract development and manufacturing organisation (CDMO) and Medspray BV (“Medspray”), a manufacturer of high tech spray nozzles, announce that they have now completed the previously announc...

Recipharm and Medspray Launch Resyca Joint Venture to Exploit Novel Softmist Technology for Pharmaceutical Applications     ENSCHEDE, the Netherlands, February 01, 2021 / B3C newswire / --Recipharm AB (publ) (“Recipharm”), a leading contract development and manufacturing organisation (CDMO) and Medspray BV (“Medspray”), a manufacturer of high tech spray nozzles, announce that they have now completed the previously announced joint venture and established Resyca ...

XPhyto Therapeutics Corp.: XPhyto Announces Drug Formulation Strategy and 2021 Milestones Innovation to Impact Four clinical studies in neurological indications in 2021 Development of oral biosensor and contract development & manufacturing Psychedelic transdermal and sublingual drug formulation development VANCOUVER, BC / ACCESSWIRE / January 28, 2021 / XPhyto Therapeutics Corp. ( XPhyto" or the " Company") is pleased to announce its drug formulation and delivery business strategy and milestone...

Cold chain in 2021 Dave Williams predictions for COVID-19s continued influence on the industry As we enter 2021 and reflect on 2020, the pandemic pushed pharmaceutical and cold chain industries to work in unprecedented ways to innovate through vaccine development, temperature-controlled packages that met the needs of new deep-frozen vaccine storage and increased demand for existing products. These cold chain industry predictions highlight how COVID-19’s influence persists in 2021 and may have...

Features Observation Of Neutralizing Antibodies To SARS-CoV-2 Advancement Of Viral Vaccine Platform And T-cell Diagnostic To Address Emerging SARS-CoV-2 Strains BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys" or "Company") is pleased to provide a corporate update on recent advancements of its vaccine platforms, and viral diagnostic and corporate objectives for 2021. BioVaxys is pleased to announce that it has commenced the clinical development program for BVX-0918A, i...